Innovative Molecular Detection System Offers On-Site and Rapid Detection of SARS-CoV-2
By HospiMedica International staff writers Posted on 13 Jan 2021 |
Illustration
A compact and robust molecular detection system based on the isothermal DNA/RNA amplification method can provide on-site and rapid detection of SARS-CoV-2, making it ideal for use in airports, sport venues, pharmacies and workplaces due to its simple and fast operation procedure.
The eGGi molecular detection system developed by Winnoz Technology (Taipei, Taiwan) offers an on-site and rapid screening solution for the SARS-CoV-2 virus. By using saliva or swab specimens as sampling and without RNA extraction, the test result can be finalized in 40 minutes for anyone and anywhere. Unlike a central lab model, the eGGi point-of-care testing solution can be applied and deployed quickly, making it more cost-effective and time saving.
In addition to the eGGi molecular detection system, Winnoz also offers a vacuum assisted fingertip blood collection system named Haiim that is bundled with various testing kits to identify COVID-19 infection. The rapid screening test results can help medical staff to quickly identify the illness and proceed with appropriate treatments. The portable automatic vacuum assisted fingertip blood micro collection device is extremely efficient in comparison to current methods such as needles. The blood collected using Haiim is of sufficient volume to meet the requirements of many testing strips and requires minimal training to operate. Haiim can be applied within COVID-19 vaccine efficacy test sampling, as the blood specimen can be collected at home and sent to laboratories for testing, thus reducing the risk.
"We believe that the COVID-19 screening and vaccination efficacy test would play a more important role as vaccines roll out to bring our life back to normal." said Dr. Joses Hsiung, Winnoz Founder and CEO. "The advent of new technologies and innovations because of the challenges of the ongoing pandemic will push the global healthcare ecosystem to new boundaries. For example, how to deploy and roll out the screening, vaccines and vaccine efficacy testing quickly would be very crucial. eGGi, a rapid and on-site isothermal PCR, is able to support screening for anyone and anywhere, meanwhile Haiim, a unique blood microsampling solution, makes vaccine efficacy test sampling easier and safer."
Related Links:
Winnoz Technology
The eGGi molecular detection system developed by Winnoz Technology (Taipei, Taiwan) offers an on-site and rapid screening solution for the SARS-CoV-2 virus. By using saliva or swab specimens as sampling and without RNA extraction, the test result can be finalized in 40 minutes for anyone and anywhere. Unlike a central lab model, the eGGi point-of-care testing solution can be applied and deployed quickly, making it more cost-effective and time saving.
In addition to the eGGi molecular detection system, Winnoz also offers a vacuum assisted fingertip blood collection system named Haiim that is bundled with various testing kits to identify COVID-19 infection. The rapid screening test results can help medical staff to quickly identify the illness and proceed with appropriate treatments. The portable automatic vacuum assisted fingertip blood micro collection device is extremely efficient in comparison to current methods such as needles. The blood collected using Haiim is of sufficient volume to meet the requirements of many testing strips and requires minimal training to operate. Haiim can be applied within COVID-19 vaccine efficacy test sampling, as the blood specimen can be collected at home and sent to laboratories for testing, thus reducing the risk.
"We believe that the COVID-19 screening and vaccination efficacy test would play a more important role as vaccines roll out to bring our life back to normal." said Dr. Joses Hsiung, Winnoz Founder and CEO. "The advent of new technologies and innovations because of the challenges of the ongoing pandemic will push the global healthcare ecosystem to new boundaries. For example, how to deploy and roll out the screening, vaccines and vaccine efficacy testing quickly would be very crucial. eGGi, a rapid and on-site isothermal PCR, is able to support screening for anyone and anywhere, meanwhile Haiim, a unique blood microsampling solution, makes vaccine efficacy test sampling easier and safer."
Related Links:
Winnoz Technology
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans